LLY
NYSE · Pharmaceuticals
Eli Lilly and Co.
$1,189.35
+19.49 (+1.67%)
LLY News30 articles
Pfizer Stock Rises as Core Drug Growth Offsets COVID Decline
Pfizer (PFE) shares rose 0.9% after Q2 results beat estimates, with non-COVID drug growth offsetting a steep decline in COVID product sales.
Dow Advances as Tech Spending Bets Fuel Mixed Market Close
The Dow advanced on AI spending expectations, while the Nasdaq slipped. Amgen, Lilly, and Disney rose; SpaceX and AMD fell. Markets await Friday's jobs report.
Dow Rises on Rate-Sensitive Gains While Market Breadth Weakens
The Dow gained 0.87% even as private payrolls missed forecasts and ISM prices jumped. Nasdaq and small caps declined, with weak breadth and healthcare outperforming tech.
Pfizer Stock Rises as Non-COVID Drugs Offset Pandemic Revenue Slump
Pfizer's Q2 beat estimates as four growth brands offset COVID revenue declines. Shares rose 1.48% premarket.
Stock Futures Rise as Investors Favor AI Profitability Over Spending
US stock futures advanced as investors differentiated between AI companies with strong earnings and those with heavy spending, with Nvidia and Arista Networks gaining.
CVS Raises Guidance as Aetna Powers Q2 Beat
CVS Health raised its 2026 EPS outlook after a strong Q2, with Aetna contributing nearly all of the operating-profit increase. The stock rose in premarket trading.
Lilly's Q2 Growth Hinges on Mounjaro, Zepbound as Sales Projection Leans Heavily on Weight-Loss Franchise
Eli Lilly (LLY) is set to report Q2 earnings Wednesday, with Mounjaro and Zepbound expected to contribute 98% of revenue growth. Pre-market shares rose 2.2% after a five-day slide.
Novo Nordisk Slips 4% as Profit Beat Fails to Quell Wegovy Worries
Novo Nordisk shares dropped 4% in Copenhagen after Q2 profit beat estimates, but concerns over Wegovy and pipeline setbacks weighed on sentiment.
Amgen Lifts 2026 Forecast as Five Growth Brands Offset $772M Slump
Amgen (AMGN) raised its 2026 guidance after Q2 revenue beat estimates, as five growth brands added $923M in sales, offsetting a $772M decline from five struggling products.
Novo Nordisk ADR Slides Despite Strong Q2, Danish Shares Await Catch-Up
Novo Nordisk's ADR dropped 6.8% despite Q2 earnings surpassing forecasts, as investors weigh pipeline impairments and competitive pressures.
Stock Futures Climb as Oil Slumps Ahead of Key Jobs Report and AI Earnings
US stock futures advanced Monday as oil prices plunged over 6% on diplomatic hopes, while investors braced for July jobs data and a busy week of major tech earnings.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
Wall Street Kicks Off August with Modest Gains Ahead of Jobs Report
The S&P 500 gained 0.7% on Friday, though declining stocks outnumbered advancers. Investors await July payrolls data, with Amazon leading gains while Apple fell.
Tech Gains Mask Narrow Market as Jobs Report Looms
Stocks closed higher this week, but tech-led gains masked a narrow rally. Investors now await the July jobs report, which could influence Fed rate hike expectations.
AI Cash Flow Concerns Split Tech Stocks as S&P 500 Gains 1.1%
Wall Street ended higher last week, but AI investment scrutiny deepened. Microsoft and Amazon rallied on strong cloud results, while Apple and Meta slid on cash flow worries.
Apnimed Surges 56% in Nasdaq Debut as FDA Decision Looms
Apnimed (NASDAQ:APMD) closes its first day up 56% at $25, valuing the company near $1 billion as the FDA reviews its sleep apnea treatment.
Novo Nordisk Shares Plunge 9% as ZEUS Trial Fails to Show Cardiovascular Benefit
Novo Nordisk shares fell sharply after ZEUS trial data showed no significant cardiovascular benefit, wiping out $20.5 billion in market cap and underscoring heavy reliance on GLP-1 franchise.
AtaiBeckley Shares Steady at $7.17 as CVR Valued at 42 Cents in Lilly Deal
AtaiBeckley shares remain flat at $7.17, 42 cents above Eli Lilly's cash offer, with the contingent value rights (CVR) implied at 16.8% of the $2.50 maximum payout.
Viking Therapeutics Faces Cash Runway Questions Ahead of Q2 Report
Viking Therapeutics shares fell 6.2% last week as analysts increased Q2 loss estimates by 24% to $1.23 per share. The company's cash runway faces scrutiny ahead of earnings on July 29.
AtaiBeckley Shares Trade Above Lilly Bid as Milestone Rights Valued at 18%
AtaiBeckley shares ended Monday at $7.19, above Eli Lilly's cash bid, as milestone rights are valued at $0.44, or 18% of the full $2.50 potential.
AtaiBeckley Shares Reflect Merger CVR Valued at 19% of Par
AtaiBeckley shares surged 39.7% last week to $7.22, with the merger CVR valued at $0.47, representing 18.8% of its $2.50 maximum payout.
Pfizer Gains 3.6% as Dividend Yield Attracts Income Investors
Pfizer (PFE) shares climbed 3.6% as its 6.9% dividend yield attracted income-focused investors, despite unchanged analyst estimates and a slight earnings forecast cut.
AtaiBeckley Merger Value Reflects 14% of CVR Face Value
AtaiBeckley shares trade at $7.091, 34 cents above Eli Lilly's cash offer, implying a CVR value of 13.6% of its maximum $2.50 face value.
TrumpRx Program Shows Limited Big Pharma Impact
TrumpRx's 79 presidential deals cover just 10% of branded drugs from 17 pharma firms, far below the touted 800. Major drugs like Ibrance and Biktarvy are excluded, limiting investor risk.
Eli Lilly Shares Gain on Atai Deal with $1 Billion Milestone Potential
Eli Lilly shares edged up 1.08% on a $3.8B deal with Atai Life Sciences, which could unlock up to $1 billion in milestone payments for psychedelic depression drugs.
AtaiBeckley Soars on Lilly Deal; Market Weighs Milestone Value
AtaiBeckley shares surged 31% to $7.04 after Eli Lilly agreed to acquire the company for up to $9.25 per share, including contingent payments. The stock sits just $0.29 above the cash offer, reflecting cautious market expectations for milestones.
VivoSim Labs Soars on $5M Lilly Milestone, But Revenue Base Remains Tiny
VivoSim Labs hit a $5M milestone from Eli Lilly, but its revenue base of $131K and a 500% growth target highlight ongoing cash challenges.
Eli Lilly's $50 Obesity Drug Strategy: Volume vs. Price
Eli Lilly's stock hovers near record highs as a new Medicare program offers $50/month access to its obesity drugs. First-quarter revenue surged 56%, but lower realized prices trimmed growth.
Pfizer Stock Rebounds After HSBC Downgrade, Dividend Yield Nears 7%
Pfizer shares recover some losses after HSBC downgrades the stock to Hold, slashing its price target by $4 to $28, as the dividend yield remains near 7%.
Pfizer's 7% Yield Beckons as Stock Lingers Near $24
Pfizer (PFE) trades near $24 with a 7.1% yield after a flat week. The company's Q1 dividends rivaled R&D spending, underscoring a focus on shareholder returns.